

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

John D. Noti

Title:

MYELOID CELL PROMOTER

AND CONSTRUCTS CONTAINING SAME

Appl. No.:

09/476,202

Filing Date:

01/03/2000

Examiner:

Katcheves, Konstantina T

Art Unit:

1636

## Atty. Dkt. No. 052544-0108 \*\*KOFFICE \*\*ing deposited sufficient d to: \*\*The control of the co I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop NON-FEE AMENDMENT, Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on the date below. Robert N. Young (Printed Name) (Signature) June 19, 2003 (Date of Deposit)

## AMENDMENT AND RESPONSE

Mail Stop NON-FEE AMENDMENT Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

This communication is responsive to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (Notice) dated May 19, 2003, concerning the above-referenced patent application. The one-month period for responding to the Notice is set to expire on June 19, 2003. Accordingly, applicants believe that this response is timely filed. No fee is believed to be due for this filing. Should any fee be due, the Patent Office is hereby authorized to charge such fees to deposit account No. 50-2350. No extensions of time are believed to be due for this filing; however, should any extensions of time be needed for timely acceptance of papers submitted herewith, applicants hereby petition for such extension under 37 C.F.R. §1.136 and authorize payment of any such extensions fees to Deposit Account No. 50-2350. For the purpose of charging said deposit account, duplicates of pages 1 and the signature page of this response are submitted herewith.

The amendments presented below are in compliance with the revised amendment format permitted in the Notice from the Office of Patent Legal Administration of the U.S. Patent and Trademark Office dated February 10, 2003, and published at 1267 OG 106 on February 25, 2003. Thus, the provisions of 37 CFR 1.121(a), (b), (c) and (d) are waived for amendments made in this application to the claims, specification, and drawings.

**Amended Drawings** begin on page 3 of this document, and include replacement drawing sheet.

Remarks begin on page 8 of this document.

Please amend Figures 1, 3, 8 and 9 to read as follows: